Drugs / MRT5407
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05553301 | Oct 2022 → Jan 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT5407 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05553301 ↗ |
| Modality | Messenger RNA (mRNA) | “Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407” NCT05553301 ↗ |
| Route | Intramuscular | “Route of Administration: Intramuscular Injection” NCT05553301 ↗ |